Free shipping on all orders over $ 500

HS-173

Cat. No. M3731
HS-173 Structure
Size Price Availability Quantity
5mg USD 90  USD90 In stock
10mg USD 155  USD155 In stock
25mg USD 320  USD320 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

HS-173 inhibited the PI3K signaling pathway, and showed anti-proliferative effects on cancer cells. Also, HS-173 induced cell cycle arrest at the G(2)/M phase and apoptosis. In addition, HS-173 decreased the expression HIF-1α and VEGF which play an important role in angiogenesis. Furthermore, HS-173 diminished blood vessel formation in the Matrigel plug assay in mice. Combined treatment of Sorafenib and HS-173 synergistically inhibited the viability of Panc-1 cells (combination index<1). HS-173 demonstrated anti-proliferative effects in NSCLC cells and effectively inhibited the PI3K signaling pathway in a dose‑dependent manner.HS-173 reduced the expression of α-smooth muscle actin (α-SMA), vimentin, PAI-1, fibronectin, collagen type I, collagen IV and TGF-β-activated smad2/3 in PD-derived primary fibroblasts.

Customer Product Validations & Biological Datas
Source Oncotarget (2016). Figure 2. HS-173
Method wound healing assay
Cell Lines Miapaca-2 and Aspc-1 cells
Concentrations 1 μM
Incubation Time 24 h
Results In three pancreatic cancer cell lines, TGF-β treated group was healed over 90% of the wound area within 16 h, whereas cells in control group were slowly migrated. However, HS-173 successfully suppressed TGF-β induced cell migration dose-dependently in all pancreatic cancer cell lines
Protocol (for reference only)
Cell Experiment
Cell lines T47D, SK-BR3, MCF7 cells
Preparation method Using a MTT assay to performe cell viability . Briefly, plating T47D cells in 96-well plates for 24 h. Then,removing the medium and treating cells with either DMSO as a control or various concentrations of inhibitors. The final concentration of DMSO in the medium was ≤0.1% (v/v). After incubating the cells for 48 h, adding 20 μL MTT solution (5 mg/mL) to each well for another 4 h at 37 °C. The formazan crystals that formed are dissolved in DMSO (100 μL/well) by constant shaking for 5 min. Then read the plate on a microplate reader at 540 nm. Three replicate wells are used for each analysis. The median inhibitory concentration (IC50, defined as the drug concentration at which cell growth is inhibited by 50%) is assessed from the dose−response curves. To assess the effect of compounds on cell proliferation, culturing T47D cells with compound (0.1−100 μM) for 48 h before MTT analysis.
Concentrations ~50 μM
Incubation time 48 hours
Animal Experiment
Animal models Male BALB/c mice with CCl4-induced liver fibrosis
Formulation Dissolved in DMSO, and then mixture (DMSO:PEG400:D.W. = 1:5:4).
Dosages ~20 mg/kg
Administration p.o.
Chemical Information
Molecular Weight 422.46
Formula C21H18N4O4S
CAS Number 1276110-06-5
Solubility (25°C) DMSO 10 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Son MK, et al. Sci Rep. HS-173, a Novel PI3K Inhibitor, Attenuates the Activation of Hepatic Stellate Cells in Liver Fibrosis.

[2] Lee H, et al. Oncol Rep. A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells.

[3] Jung KH, et al. Int J Oncol. A novel PI3K inhibitor alleviates fibrotic responses in fibroblasts derived from Peyronie's plaques.

[4] Yun SM, et al. Cancer Lett. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.

[5] Lee H, et al. Cancer Lett. HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis.

Related PI3K Products
SNV4818

SNV4818 is a potential best-in-class (best-in-class) mutation-selective PI3K-α inhibitor with excellent selectivity for the H1047X mutant and moderate selectivity for the related E545/542X mutant.

hSMG-1 inhibitor 11j

hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of hSMG-1, with an IC50 of 0.11 nM.

RLY-2608

RLY-2608 is a first-in-class, orally active, selective inhibitor of PI3Ka metabolism.

EDI048

EDI048 is an orally active Cryptosporidium PI4K inhibitor for the research of cryptosporidiosis.

PI3Kδ-IN-13

PI3Kδ-IN-13 is a PI3Kδ inhibitor (IC50=2.6 nM).

  Catalog
Abmole Inhibitor Catalog




Keywords: HS-173 supplier, PI3K, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.